Dikova VR,
Principe S, Bagan JV. Salivary inflammatory proteins in patients with oral
potentially malignant disorders. J Clin Exp Dent. 2019;11(7):e659-64.
doi:10.4317/jced.55917
http://dx.doi.org/10.4317/jced.55917
______________________________________________________________________________________________________________________
References
|
1. Mishra R. Biomarkers of
oral premalignant epithelial lesions for clinicalapplication. Oral Oncol.
2012;48:578-84. |
|
|
|
|
|
2. Arellano-Garcia
ME, Hu S, Wang J, Henson B, Zhou H, Chia D, Wong DT.Multiplexed
immunobead-based assay for detection of oral cancer protein biomarkers in
saliva. Oral Dis. 2008;14:705-12. |
|
|
|
|
|
3. Reibel
J. Prognosis of oral pre-malignant lesions: significance of clinical,
histopathological, and molecular biological characteristics. Crit Rev Oral
Biol Med. 2003;14(1):47-62. https://doi.org/10.1177/154411130301400105 PMID: 12764019. |
|
|
|
|
|
4. Epstein
JB, Zhang L, Rosin M. Advances in the diagnosis of oral premalignant and
malignant lesions. J Can Dent Assoc. 2002Nov;68(10):617-21.
Review. PubMed PMid: 12410942 |
|
|
|
|
|
5. Hu
S, Arellano M, Boontheung P, Wang J, Zhou H, Jiang J, et al. Salivary
proteomics for oral cancer biomarker discovery. Clin Cancer Res.
2008;14:6246-52. |
|
|
|
|
|
6. Zhang
CZ, Cheng XQ, Li JY, Zhang P, Yi P, Xu X, et al. Saliva in the diagnosis of
diseases. Int J Oral Sci. 2016;8:133-7. |
|
|
|
|
|
7. Aas
JA, Paster BJ, Stokes LN, Olsen I, Dewhirst FE. Defining the normal bacterial
flora of the oral cavity. J Clin Microbiol. 2005;43:5721-32. https://doi.org/10.1128/JCM.43.11.5721-5732.2005 |
|
|
|
|
|
8. Yoshizawa
JM, Schafer CA, Schafer JJ, Farrell JJ, Paster BJ, Wong DT. Salivary
biomarkers: toward future clinical and diagnostic utilities. Clin Microbiol
Rev. 2013;26:781-91. https://doi.org/10.1128/CMR.00021-13 |
|
|
|
|
|
9. Rhodus
NL, Ho V, Miller CS, Myers S, Ondrey F. NF-kappaB dependent cytokine levels
in saliva of patients with oral preneoplastic lesions and oral squamous cell
carcinoma. Cancer Detect Prev. 2005;29:42-5. https://doi.org/10.1016/j.cdp.2004.10.003 |
|
|
|
|
|
10. Brailo
V, Vucićević-Boras V, Cekić-Arambasin A, Alajbeg IZ, Milenović A, Lukac J.
The significance of salivary interleukin 6 and tumor necrosis factor alpha in
patients with oral leukoplakia. Oral Oncol. 2006;42:370-3. |
|
|
|
|
|
11. Sharma
M, Bairy I, Pai K, Satyamoorthy K, Prasad S, Berkovitz B, Radhakrishnan R.
Salivary IL-6 levels in oral leukoplakia with dysplasia and its clinical
relevance to tobacco habits and periodontitis. Clin Oral Investig.
2011;15:705-14. https://doi.org/10.1007/s00784-010-0435-5 |
|
|
|
|
|
12. Juretić
M, Cerović R, Belušić-Gobić M, Brekalo Pršo I, Kqiku L, Špalj S,
Pezelj-Ribarić S. Salivary levels of TNF-α and IL-6 in patients with oral
premalignant and malignant lesions. Folia Biol (Praha). 2013;59:99-102.
PMid: 23746176. |
|
|
|
|
|
13. Kaur
J, Jacobs R. Proinflammatory cytokine levels in oral lichen planus, oral
leukoplakia, and oral submucous fibrosis. J Korean Assoc Oral Maxillofac
Surg. 2015 ;41:171-5. https://doi.org/10.5125/jkaoms.2015.41.4.171 |
|
|
|
|
|
14.
Brailo V, Vucicevic-Boras V, Lukac J,
Biocina-Lukenda D, Zilic-Alajbeg I, Milenovic A, et al. Salivary and serum interleukin 1 beta,
interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia
and oral cancer. Med Oral Patol Oral Cir Bucal. 2012;17:e10-5. https://doi.org/10.4317/medoral.17323 |
|
|
|
|
|
15.
Bagan L, Sáez GT, Tormos MC, Labaig-Rueda C,
Murillo-Cortes J, Bagan JV. Salivary
and serum interleukin-6 levels in proliferative verrucous leukoplakia. Clin
Oral Investig. 2016;20:737-43. |
|
|
|
|
|
16. Pezelj-Ribaric
S, Prso IB, Abram M, Glazar I, Brumini G, Simunovic-Soskic M. Salivary levels
of tumor necrosis factor-alpha in oral lichen planus. Mediators Inflamm.
2004;13:131-3. https://doi.org/10.1080/09629350410001688530 |
|
|
|
|
|
17. Rhodus
NL, Cheng B, Myers S, Miller L, Ho V, Ondrey F. The feasibility of monitoring
NF-kappaB associated cytokines: TNF-alpha, IL-1alpha, IL-6, and IL-8 in whole
saliva for the malignant transformation of oral lichen planus. Mol Carcinog. 2005;44:77-82. https://doi.org/10.1002/mc.20113 |
|
|
|
|
|
18. Zhang
Y, Lin M, Zhang S, Wang Z, Jiang L, Shen J, et al. NF-kappaB-dependent
cytokines in saliva and serum from patients with oral lichen planus: a study
in an ethnic Chinese population. Cytokine. 2008;41:144-9. https://doi.org/10.1016/j.cyto.2007.11.004 |
|
|
|
|
|
19. Zhang
Y, Liu W, Zhang S, Dan H, Lu R, Wang F, et al. Salivary and serum
interleukin-18 in patients with oral lichen planus: a study in an ethnic
Chinese population. Inflammation. 2012;35:399-404. https://doi.org/10.1007/s10753-011-9327-3 |
|
|
|
|
|
20. Dineshkumar
T, Ashwini BK, Rameshkumar A, Rajashree P, Ramya R, Rajkumar K. Salivary and
Serum Interleukin-6 Levels in Oral Premalignant Disorders and Squamous Cell
Carcinoma: Diagnostic Value and Clinicopathologic Correlations. Asian Pac J
Cancer Prev. 2016;17:4899-4906. PMid: 28032493 PMCid:
PMC5454693 |
|
|
|
|
|
21. Warnakulasuriya
S, Johnson NW, van der Waal I. Nomenclature and classification of potentially
malignant disorders of the oral mucosa. J Oral Pathol Med. 2007;36:575-80. |
|
|
|
|
|
22. van
der Waal I. Oral leukoplakia: A diagnostic challenge for clinicians and
pathologists. Oral Dis. 2019;25:348-349. PMid: 30203899 |
|
|
|
|
|
23. Lumerman
H, Freedman P, Kerpel S. Oral epithelial dysplasia and the development of
invasive squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol
Endod. 1995;79:321-9. PMid: 7621010. |
|
|
|
|
|
24. Silverman
S Jr, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation.
A follow-up study of 257 patients. Cancer. 1984;53:563-8. https://doi.org/10.1002/1097-0142(19840201)53:3<563::AID-CNCR2820530332>3.0.CO;2-F PMid: 6537892. |
|
|
|
|
|
25. Shirani
S, Kargahi N, Razavi SM, Homayoni S. Epithelial dysplasia in oral cavity.
Iran J Med Sci. 2014;39:406-17. PMid: 25242838 PMCid:
PMC4164887 |
|
|
|
|
|
26. Pinholt
EM, Rindum J, Pindborg JJ. Oral cancer: a retrospective study of 100 Danish
cases. Br J Oral Maxillofac Surg. 1997;35:77-80. |
|
|
|
|
|
27. Amagasa T, Yamashiro M,
Ishikawa H. Oral Leukoplakia Related to Malignant Transformation. Oral Sci
Int. 2006;3:44-55. |
|
|
|
|
|
28. Pindborg
JJ, Renstrup G, Poulsen HE, Silverman S Jr. Studies in oral leukoplakias. V.
clinical and histologic signs of malignancy. Acta
Odontol Scand. 1963;21:407-14. https://doi.org/10.3109/00016356309028203 |
|
|
|
|
|
29. Axéll
T. A prevalence study of oral mucosal lesions in an adult Swedish population.
Odontol Revy Suppl. 1976;36:1-103. PMid: 186740. |
|
|
|
|
|
30. Berra
A, Sterin-Borda L, Bacman S, Borda E. Role of salivary IgA in the
pathogenesis of Sjögren syndrome. Clin Immunol. 2002;104:49-57. https://doi.org/10.1006/clim.2002.5228 |
|
|
|
|
|
31. Marchetti
P, Benzi L, Masoni A, Cecchetti P, Giannarelli R, Di Cianni G, et al.
Salivary insulin concentrations in type 2(non-insulin-dependent) diabetic
patients and obese non-diabetic subjects: relationship to changes in plasma
insulin levels after an oral glucose load. Diabetologia.
1986;29:695-8. https://doi.org/10.1007/BF00870278 |
|
|
|
|
|
32. Emmons
W. Accuracy of oral specimen testing for human immunodeficiency virus. Am J
Med. 1997;102:15-20. https://doi.org/10.1016/S0002-9343(97)00033-8 PMid: 9217634 |
|
|
33. Giannobile
WV, Beikler T, Kinney JS, Ramseier CA, Morelli T, Wong DT. Saliva as a
diagnostic tool for periodontal disease: current state and future directions.
Periodontol 2000. 2009;50:52-64. https://doi.org/10.1111/j.1600-0757.2008.00288.x |
|
|
|
|
|
34. Silberring
J, Ciborowski P. Biomarker discovery and clinical proteomics. Trends Analyt
Chem. 2010;29:128. https://doi.org/10.1016/j.trac.2009.11.007 |
|
|
|
|
|
35. Medzhitov
R. Origin and physiological roles of inflammation. Nature.
2008;454:428-35. |
|
|
|
|
|
36. Bigler
LR, Streckfus CF, Copeland L, Burns R, Dai X, Kuhn M, Martin P, Bigler SA.
The potential use of saliva to detect recurrence of disease in women with
breast carcinoma. J Oral Pathol Med. 2002;31:421-31. https://doi.org/10.1034/j.1600-0714.2002.00123.x |
|
|
|
|
|
37. Wang
CY, Mayo MW, Baldwin AS Jr. TNF- and cancer therapy-induced apoptosis:
potentiation by inhibition of NF-kappaB. Science. 1996;274:784-7. |
|
|
|
|
|
38. Pikarsky
E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kappaB
functions as a tumour promoter in inflammation-associated cancer. Nature.
2004;431:461-6. |
|
|
|
|
|
39. Sahibzada
HA, Khurshid Z, Khan RS, Naseem M, Siddique KM, Mali M, et al. Salivary IL-8,
IL-6 and TNF-α as Potential
Diagnostic Biomarkers for Oral Cancer. Diagnostics (Basel). 2017;7. pii: E21. |
|
|
|
|
|
40. Lawrence
T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb
Perspect Biol. 2009;1:a001651. |
|
|
|
|
|
41. Chen
Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, et al. Expression
of proinflammatory and proangiogenic cytokines in patients with head and neck
cancer. Clin Cancer Res. 1999;5:1369-79. PMid:10389921 |
|
|
|
|
|
42. Mann
EA, Spiro JD, Chen LL, Kreutzer DL. Cytokine expression by head and neck
squamous cell carcinomas. Am J Surg. 1992;164:567-73. PubMed
PMid:1463101 |
|
|
|
|
|
43. Nibali
L, Fedele S, D'Aiuto F, Donos N. Interleukin-6 in oral diseases: a review.
Oral Dis. 2012;18:236-43. |
|
|
|
|
|
44. Narang R, Mittal L,
Gupta YK, Roseka, R Verma R. Salivary biomarkers for periodontal diseases-A
review. Bangladesh Journal of Medical Science. 2013;12:244-249. |
|
|
|
|
|
45. Chang
KP, Kao HK, Wu CC, Fang KH, Chang YL, Huang YC, et al. Pretreatment
interleukin-6 serum levels are associated with patient survival for oral
cavity squamous cell carcinoma. Otolaryngol Head Neck Surg. 2013;148:786-91. |
|